In cases where a monocytic/myelomonocytic blast component is suspected (5–10% of AML cases [20]), an additional “monocytic” tube can be added, including markers CD33, CD45, CD64, CD11b, CD14, CD4, CD34, and HLA-DR [8,9,40]. This evidence concerns the gene CD33 and acute myeloid leukemia.